Vaxcyte, Inc.
Financials
Valuation Metrics
Vaxcyte, Inc.'s Market Cap is $9.23B. At end of 2025 it was $6.28B. Ranked #917 of 3,116 in US market (top 29%), #288 of 1,470 on NASDAQ (top 20%), #44 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 17%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $9.23B | US#917/3,116 Sec#44/265 |
| Revenue | $0.00 | US#2,862/3,116 Sec#194/265 |
| Net Income | $-1.06B | US—/3,116 Sec—/265 |
| Total Assets | $3.14B | US#1,781/3,116 Sec#46/265 |
| Net Assets | $2.76B | US#1,025/3,116 Sec#35/265 |
| Employees | 507 | US#2,265/3,116 Sec#82/265 |
| Value | ||
| P/B | 3.35x | US#1,960/3,116 Sec#113/265 |
| FCF Yield | -13.03% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -38.59% | US#2,617/3,116 Sec#135/265 |
| ROA | -33.91% | US#2,910/3,116 Sec#169/265 |
| Financial Health | ||
| Debt Ratio | 13.79% | US#153/3,116 Sec#63/265 |
| Total Debt | $115M | US#2,400/3,116 Sec#110/265 |
| FCF | $-1.20B | US#2,975/3,116 Sec#260/265 |
| Cash | $183M | US#1,801/3,116 Sec#116/265 |
| Current Ratio | 5.72x | US#408/3,116 Sec#126/265 |
| Performance | ||
| 1Y Return | 38.61% | US#414/3,116 Sec#63/265 |
| 1M Return | 9.02% | US#229/3,116 Sec#20/265 |
| From 52W High | -31.65% | US#1,801/3,116 Sec#110/265 |
| 1Y MDD | -27.95% | US#1,177/3,116 Sec#56/265 |
| Trading | ||
| Volume | 1,705,336 shares | US#862/3,116 Sec#87/265 |
| Trading Value | $106M | US#681/3,116 Sec#44/265 |
| Per Share | ||
| EPS | $-7.15 | US—/3,116 Sec—/265 |
| BPS | $18.53 | US#1,306/3,116 Sec#32/265 |
Company Info
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.